BCM
VKTX icon

Boone Capital Management’s Viking Therapeutics VKTX Stock Holding History

Boone Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-209,853
Closed -$8.44M – 16
2024
Q4 		$8.44M Buy
209,853
+16,964
+9% +$967K 2.85% 13
2024
Q3 		$12.2M Buy
192,889
+18,123
+10% +$1.06M 3.17% 15
2024
Q2 		$9.26M Sell
174,766
-135,696
-44% -$8.89M 2.42% 17
2024
Q1 		$25.5M Buy
+310,462
New +$13.8M 5.15% 9

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Boone Capital Management's VKTX Position: Q1 2025 in Review

Boone Capital Management sold out of Viking Therapeutics (VKTX) in Q1 2025, closing a stake of 209,853 shares — an estimated $8.44M sold.

Boone Capital Management first reported a position in VKTX in Q1 2024 and held it in 4 quarters. The position peaked at $25.5M in Q1 2024. 372 funds tracked by Wall St. Rank hold VKTX as of Q1 2025.

  • Boone Capital Management reported no remaining Viking Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Boone Capital Management sold 209,853 Viking Therapeutics shares in Q1 2025, an estimated $8.44M.
  • Boone Capital Management first reported a position in Viking Therapeutics in Q1 2024 and held it in 4 quarters.
  • Boone Capital Management's Viking Therapeutics position peaked at $25.5M in Q1 2024.
  • 372 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2025.

Based on Boone Capital Management's 13F filing for Q1 2025, filed 15 May 2025.